Maprotilina Ratiopharm (Maprotiline Hydrochloride)

Maprotiline, a tetracyclic antidepressant that modulates norepinephrine pathways, is indicated for:

• Major depressive disorder: reduces depressive symptoms in adults.
• Depressive episodes with melancholia: improves mood, sleep and energy levels.
• Depressive disorder with anxiety features: alleviates anxiety accompanying depression.

• Maprotiline inhibits the reuptake of norepinephrine by blocking the norepinephrine transporter, leading to increased synaptic concentrations of norepinephrine. This enhancement of noradrenergic neurotransmission contributes to mood elevation and alleviation of depressive symptoms. The drug shows minimal effect on serotonin and dopamine reuptake, distinguishing it from other antidepressant classes.

Common Side Effects

• Dry mouth: reduced salivary flow causing discomfort.
• Drowsiness or sedation: increased sleepiness, especially at treatment initiation.
• Constipation: slowed gastrointestinal motility.
• Weight gain: modest increase in body weight over time.
• Dizziness: sensation of light‑headedness or imbalance.
• Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects

• Cardiac arrhythmias: irregular heart rhythms requiring medical attention.
• Seizures: risk of convulsive episodes, particularly at high doses.
• Severe hypotension: marked drop in blood pressure causing faintness.
• Hepatotoxicity: liver enzyme elevations or injury.
• Agranulocytosis: dangerously low white‑blood‑cell count.
• Neuroleptic malignant‑like syndrome: rare but life‑threatening reaction with fever and muscle rigidity.

Before initiating therapy, consider the following precautions:

• Cardiac assessment: evaluate history of heart disease or arrhythmias.
• Liver function: monitor hepatic enzymes in patients with hepatic impairment.
• Renal function: adjust use in severe renal insufficiency.
• Concomitant CNS depressants: avoid excessive sedation when combined with alcohol or other sedatives.
• Elderly patients: start at low dose and monitor for orthostatic hypotension.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Maprotiline may interact with several drug classes. Clinicians should review patient medication lists carefully.

Major Interactions (Avoid)

• MAO inhibitors: risk of hypertensive crisis or serotonin syndrome.
• Other norepinephrine reuptake inhibitors: additive cardiovascular effects.
• QT‑prolonging agents: increased risk of arrhythmias.

Moderate Interactions (Monitor Closely):\n- CNS depressants (benzodiazepines, opioids): enhanced sedation.

• Anticholinergic drugs: heightened anticholinergic burden.
• CYP2D6 substrates: altered metabolism may require dose adjustment.